| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.97(B) |
| Last
Volume: |
944,850 |
Avg
Vol: |
1,397,134 |
| 52
Week Range: |
$76.22 - $100.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
139,229 |
182,993 |
316,353 |
658,922 |
| Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$62,013,572 |
| Total People Sold |
5 |
5 |
6 |
8 |
| Total Sell Transactions |
11 |
15 |
24 |
58 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-16 |
4 |
AS |
$64.65 |
$129,307 |
I/I |
(2,000) |
20,609 |
|
- |
|
| Bate Kenneth |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
8,675 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
22,050 |
|
- |
|
| Fuchs Henry J |
EVP, Chief Medical Officer |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,600 |
54,973 |
|
- |
|
| Spiegelman Daniel K |
EVP, Chief Financial Officer |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,200 |
46,200 |
|
- |
|
| Davis George Eric |
SVP, General Counsel |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
50,108 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
62,262 |
|
- |
|
| Mueller Brian |
VP, Corporate Controller |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
2,200 |
8,860 |
|
- |
|
| Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
15,670 |
|
- |
|
| Young William D |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
8,675 |
|
- |
|
| Lewis Alan |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
19,300 |
|
- |
|
| Lawlis V Bryan |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
14,300 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
37,800 |
125,901 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-15 |
4 |
AS |
$68.55 |
$685,477 |
I/I |
(10,000) |
20,609 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-15 |
4 |
OE |
$12.99 |
$129,900 |
I/I |
10,000 |
30,609 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
17,425 |
|
- |
|
| Grey Michael G |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
23,050 |
|
- |
|
| Lapalme Pierre |
Director |
– • – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
3,400 |
28,050 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2013-05-14 |
5 |
GA |
$0.00 |
$0 |
I/I |
1,912 |
10,955 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2013-05-14 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,912 |
60,350 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-14 |
4 |
S |
$70.17 |
$1,052,492 |
I/I |
(15,000) |
20,609 |
|
- |
|
| Bienaime Jean Jacques |
Chief Executive Officer |
• • – |
2013-05-14 |
4 |
OE |
$12.99 |
$194,850 |
I/I |
15,000 |
35,609 |
|
- |
|
| Mueller Brian |
VP, Corporate Controller |
• – – |
2013-05-14 |
4 |
S |
$70.33 |
$348,045 |
D/D |
(4,947) |
6,660 |
|
- |
|
| Mueller Brian |
VP, Corporate Controller |
• – – |
2013-05-14 |
4 |
OE |
$21.51 |
$75,285 |
D/D |
3,500 |
10,160 |
|
- |
|
| Baffi Robert |
EVP, Technical Operations |
• – – |
2013-05-14 |
4 |
AS |
$70.00 |
$1,400,000 |
D/D |
(20,000) |
50,262 |
|
- |
|
1298 Records found
|
|
Page 9 of 52 |
|
|
0.80 (0.88%) 
